# Plain Language Summary: John W. Walsh Alpha-1 Home Infusion Act of 2022

This bill makes Medicare cover a specific treatment for people with Alpha-1 Antitrypsin Deficiency, a genetic disorder that causes severe lung damage and emphysema. Right now, Medicare doesn't pay for this treatment when it's given at home, which forces patients to travel to hospitals or clinics for their care. This bill changes that by allowing Medicare to cover the medication and nursing services needed to administer the treatment in patients' homes instead.

Here's what this means in practical terms: If you have Alpha-1 Antitrypsin Deficiency and are on Medicare, you could receive your augmentation therapy (a medication that slows lung damage) at home with a nurse present to administer it safely. Medicare would cover both the medication delivery supplies and up to two hours of nursing care per treatment session. You'd pay 20 percent of the cost, and Medicare would cover the remaining 80 percent. This is similar to how Medicare covers other home-based medical treatments.

The bill only applies to Medicare patients who are enrolled in both Part A and Part B coverage and are not in a Medicare Advantage plan. The treatment must be prescribed by a doctor, nurse practitioner, or physician assistant. The changes take effect on January 1, 2023, giving Medicare time to set up the payment system. For the relatively small number of people with this rare genetic condition, this bill removes a significant barrier to treatment by letting them receive care in the comfort of their homes rather than making frequent trips to medical facilities.

John W. Walsh Alpha-1 Home Infusion Act of 2022

John W. Walsh Alpha-1 Home Infusion Act of 2022 This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.